Besifloxacin hydrochloride

What is Besifloxacin hydrochloride?[edit | edit source]

Besifloxacin hydrochloride (Besivance) is a quinolone antimicrobial used for the treatment of bacterial conjunctivitis.

Besifloxacin

Besifloxacin-3D-balls

Besifloxacin is a fluoroquinolone antibacterial.
Besifloxacin is an 8-chloro fluoroquinolone with a N-1 cyclopropyl group.
The compound has activity against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV.
DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA.
Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division.
Besifloxacin is bactericidal with minimum bactericidal concentrations (MBCs) generally within one dilution of the minimum inhibitory concentrations (MICs).

The eye drop was approved by the United States Food and Drug Administration (FDA) on May 29, 2009.

Recommended dosage:

Instill one drop in the affected eye(s) 3 times a day, four to twelve hours apart for 7 days.

Administration:

Patients should be advised to thoroughly wash hands prior to using Besivance.
Patients should be instructed to invert closed bottle (upside down) and shake once before each use. Remove cap with bottle still in the inverted position. Tilt head back, and with bottle inverted, gently squeeze bottle to instill one drop into the affected eye(s).
Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with Besivance™.

This medicine is available in fallowing doasage form:

As 7.5 mL size bottle filled with 5 mL of besifloxacin ophthalmic suspension, 0.6%

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Besivance™ is for topical ophthalmic use only, and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye.
As with other anti-infectives, prolonged use of Besivance™ (besifloxacin ophthalmic suspension) 0.6% may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with Besivance.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Since there are no adequate and well-controlled studies in pregnant women, Besivance™ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Pregnancy Category C.

The safety and effectiveness of Besivance™ in infants below one year of age have not been established.

Active ingredient:

Inactive ingredients:

Manufactured by:

Besifloxacin hydrochloride Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.